TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?

Table 2

TNF-α SNPs and JIA therapeutic response.

Authors	Population	Drug (dosage)	Evaluation time	Number of subjects	JIA subtype	Polymorphisms	Findings
					Systemic arthritis (no. 19); FR− polyarthritis (no. 43); FR+ polyarthritis (no. 12); Persistent oligoarthritis (no. 5); Extended oligoarthritis (no. 24); Enthesitis-arthritis (no. 15); Psoriatic arthritis (no. 8); Non classified form (no. 11)	−163, −244, −376	Not found
Schmeling et al. (2006)	Caucasia; /Germany	Etanercept	3 months,; 6 months, every 6 months thereafter; (max 60 months)	137		−238GG versus −238GA/AA	No correlation
						−308GG versus −308GA/AA	−308GG genotype more frequently respond to etanercept therapy, especially in the FR− polyarthritis subgroup until 6 months of therapy.
Cimaz et al. (2007)	Caucasian/ Italy	(i) Infliximab; (3 mg/kg); (ii) Etanercept; (0.4 mg/kg); (iii) Adalimumab; (24 mg/m²)	3 months	107	Systemic arthritis (no. 29); FR− polyarthritis (no. 24); FR+ polyarthritis (no. 5); Persistent oligoarthritis (no. 4); Extended oligoarthritis (no. 27); Enthesitis-arthritis (no. 12); Psoriatic arthritis (no. 6)	−238GG/GA/AA; −308GG/GA/AA	No association between SNPs and clinical response to drugs
Basic et al. (2010)	Caucasian/ Serbia	Etanercept	1 year	66		−308G/A	−308GG SNP have response to drug significantly more frequently than −308AA SNP in polyarticular JIA